A Phase 2 Proof-of-Concept, Randomized, Placebo-Controlled Trial of CX-8998 in Essential Tremor.

ABSTRACT:

Background

Available essential tremor (ET) therapies have limitations.

Objectives

The objective of this study was to evaluate CX-8998, a selective T-type calcium channel modulator, in essential tremor.

Methods

Patients 18-75 years old with moderate to severe essential tremor were randomized 1:1 to receive CX-8998 (titrated to 10 mg twice daily) or placebo. The primary end point was change from baseline to day 28 in The Essential Tremor Rating Assessment Scale performance subscale scored by independent blinded video raters. Secondary outcomes included in-person blinded investigator rating of The Essential Tremor Rating Assessment Scale performance subscale, The Essential Tremor Rating Assessment Scale activities of daily living subscale, and Kinesia ONE accelerometry.<

SUBMITTER: Papapetropoulos S 

PROVIDER: S-EPMC8451783 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature